Abstract

The mission of the Pharmacology Core Facility (PCF) is to foster clinical pharmacology and biomarker research regarding cancer therapeutics. The Facility offers comprehensive lab services to support cancer investigators conducting clinical and preclinical drug development studies. The PCF is now comprised of an Analytical Unit and a Biofluids Unit. The labs occupy -3,465 sq ft of space within the Section of Hematology/Oncology, and also utilizes the IV therapy unit (2,662 sq ft) located directly across from the Hematology/Oncology clinic in the Duchossois Center for Advanced Medicine (DCAM). The Core currently works with 169 cancer clinical studies representing 5 UCCCC Programs, and a few tissue procurement studies. Services provided by the PCF include: ? development and implementation of analytical assays for measurement of drugs and metabolites in biological fluids ? pharmacokinetic design and writing assistance for clinical protocols; ? pharmacokinetic/pharmacodynamic modeling; ? research phlebotomy and intravenous cannulation; ? sample processing; ? urine collection; ? specimen storage, tracking and archiving;and ? electrocardiograms.

Public Health Relevance

The research supported by the PCF aims at improving the quality of life and outcome of cancer patients. We help clinical investigators individualize chemotherapy to optimize treatment effectiveness and minimize toxicity. We also facilitate discovery and measurement of biomarkers correlating with pharmacological response to a drug or disease progression.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-39
Application #
8744840
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$61,803
Indirect Cost

  Institution

Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637

  Publications

Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications